Nektar, BMS end development programme
Nektar Therapeutics Inc and Bristol Myers Squibb Co have stopped the global programme for a jointly developed cancer therapy following the failure of two clinical trials. The therapy combined bempegaldesleukin, an experimental interleukin-2 cytokine prodrug, with the checkpoint inhibitor Opdivo (nivolumab).